IGMPI facebook Clinical Research
IGMPI Logo
Faculty of Clinical Research and Drug Safety

(An Autonomous Body Recognized by Ministry of Commerce & Industry, Government of India)

Competency based placement focussed Education I Training I Research I Consultancy

ADMISSIONS NOTICE
18001031071 (Toll Free), +91 11 26512850
Regular | Part-time (Online Live Classes) Modes

Clinical Research

Ionis Pharma reports positive results from the phase 2 study of ION224, demonstrating clinical efficacy in treating NASH/MASH
Bristol Myers Squibb reports CheckMate -9DW trial of Opdivo plus Yervoy meets primary endpoint of OS to treat advanced HCC
Pfizer declares positive results from phase 3 trial of Adcetris regimen in relapsed/refractory DLBCL patients
Nuvectis Pharma reports positive preliminary data from NXP800 phase 1b trial in ovarian cancer (platinum-resistant ARID1a-mutated)
Aurobindo Pharma arm CuraTeQ reports omalizumab biosimilar candidate BP11 meets phase 1 trial endpoints
OcuTerra’s Phase II diabetic retinopathy trial misses endpoints
AstraZeneca reports positive results from the ADRIATIC phase III trial of Imfinzi in patients with limited-stage small-cell lung cancer
Viking declares positive data from Phase I oral obesity treatment trial
Phase III trial of KRAZATI meets endpoints : Bristol Myers Squibb
Moderna: Phase III Covid-19 vaccine trial meets primary endpoints
LENZ declares positive results from presbyopia treatment trial
HealthNet Global presents a ground-breaking Tele-ICU Programme at Apollo Spectra Hospitals, Delhi
NeuroGenesis declares positive data from multiple sclerosis trial
Acadia’s schizophrenia drug trial did not meet primary endpoint
Enlivex declares positive data from Phase II sepsis treatment trial